Last reviewed · How we verify
ANG-3777
ANG-3777 is a HGF mimetic Small molecule drug developed by Angion Biomedica Corp. It is currently in Phase 3 development for Diabetic kidney disease, Peripheral artery disease. Also known as: Hepatocyte growth factor mimetic, BB3.
ANG-3777 is a hepatocyte growth factor (HGF) mimetic that activates the MET receptor to promote tissue repair and regeneration.
ANG-3777 is a small molecule that acts as a hepatocyte growth factor receptor agonist. It is being studied in clinical trials for various conditions, including COVID-19 pneumonia, acute kidney injury, and hemodialysis patients.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ANG-3777 |
|---|---|
| Also known as | Hepatocyte growth factor mimetic, BB3 |
| Sponsor | Angion Biomedica Corp |
| Drug class | HGF mimetic |
| Target | MET receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
ANG-3777 is designed to mimic the biological activity of hepatocyte growth factor by binding to and activating the MET receptor tyrosine kinase. This activation promotes angiogenesis, tissue repair, and regeneration, particularly in ischemic tissues. The drug is being developed to treat conditions characterized by tissue damage and impaired vascular function.
Approved indications
- Diabetic kidney disease
- Peripheral artery disease
Common side effects
Key clinical trials
- Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass (PHASE2)
- Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects (PHASE1)
- A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777 (PHASE1)
- Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney (PHASE3)
- Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval (PHASE1)
- Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANG-3777 CI brief — competitive landscape report
- ANG-3777 updates RSS · CI watch RSS
- Angion Biomedica Corp portfolio CI
Frequently asked questions about ANG-3777
What is ANG-3777?
How does ANG-3777 work?
What is ANG-3777 used for?
Who makes ANG-3777?
Is ANG-3777 also known as anything else?
What drug class is ANG-3777 in?
What development phase is ANG-3777 in?
What does ANG-3777 target?
Related
- Drug class: All HGF mimetic drugs
- Target: All drugs targeting MET receptor
- Manufacturer: Angion Biomedica Corp — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Diabetic kidney disease
- Indication: Drugs for Peripheral artery disease
- Also known as: Hepatocyte growth factor mimetic, BB3
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing